High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers

INTRODUCTION: Tildrakizumab 200 mg/2 mL pre-filled syringe is a new preparation of tildrakizumab that is developed to facilitate patients’ compliance. This phase I clinical trial compares the local tolerability, safety, and subjects’ preferred method of administration of tildrakizumab when administe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokolakis, Georgios, Kreis, German, Falqués, Meritxell, Aparici, Mònica, Sondermann, Wiebke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388364/
https://www.ncbi.nlm.nih.gov/pubmed/35984626
http://dx.doi.org/10.1007/s13555-022-00789-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388364/
https://www.ncbi.nlm.nih.gov/pubmed/35984626
http://dx.doi.org/10.1007/s13555-022-00789-9

Ejemplares similares